SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for VerifyMe, Inc. (VRME, VRMEW) (CIK 0001104038) (OPNW) — Jun 30, 2022

VerifyMe, Inc. (VRME, VRMEW) (CIK 0001104038)
Date: June 30, 2022 · CIK: 0001104038 · Accession: 0000000000-22-007019

AI Filing Summary & Sentiment

File numbers found in text: 333-265852

Date
June 30, 2022
Author
Not clearly detected
Form
UPLOAD
Company
VerifyMe, Inc. (VRME, VRMEW) (CIK 0001104038)

Letter

United States securities and exchange commission logo June 30, 2022 Patrick White Chief Executive Officer VerifyMe, Inc. 75 S. Clinton Ave., Suite 510 Rochester, NY 14604 Re:VerifyMe, Inc. Registration Statement on Form S-3 Filed June 27, 2022 File No. 333-265852 Dear Mr. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alexander R. McClean

Show Raw Text
United States securities and exchange commission logo
June 30, 2022
Patrick White
Chief Executive Officer
VerifyMe, Inc.
75 S. Clinton Ave., Suite 510
Rochester, NY 14604
Re:VerifyMe, Inc.
Registration Statement on Form S-3
Filed June 27, 2022
File No. 333-265852
Dear Mr. White:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Alexander R. McClean